Literature DB >> 28222231

Two cases of anti-programmed cell death 1-associated bullous pemphigoid-like disease and eruptive keratoacanthomas featuring combined histopathology.

J P Bandino1, D M Perry1, C E Clarke1, R M Marchell1, D M Elston1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28222231     DOI: 10.1111/jdv.14179

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  4 in total

1.  Efficacy and safety of tetracyclines for pemphigoid: a systematic review and meta-analysis.

Authors:  Xin-Xing Jin; Xue Wang; Ying Shan; Si-Zhe Li; Qun Xu; Hong-Zhong Jin; Ya-Gang Zuo
Journal:  Arch Dermatol Res       Date:  2021-03-28       Impact factor: 3.017

2.  Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature.

Authors:  Coralie Zumelzu; Marina Alexandre; Christelle Le Roux; Patricia Weber; Alexis Guyot; Annie Levy; Françoise Aucouturier; Sabine Mignot-Grootenboer; Frédéric Caux; Eve Maubec; Catherine Prost-Squarcioni
Journal:  Front Med (Lausanne)       Date:  2018-09-27

Review 3.  A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.

Authors:  Adriana T Lopez; Larisa Geskin
Journal:  Oncologist       Date:  2018-07-17

4.  Bullous Pemphigoid in Patients Receiving Immune-Checkpoint Inhibitors and Psoriatic Patients-Focus on Clinical and Histopathological Variation.

Authors:  Dennis Niebel; Dagmar Wilsmann-Theis; Thomas Bieber; Mark Berneburg; Joerg Wenzel; Christine Braegelmann
Journal:  Dermatopathology (Basel)       Date:  2022-03-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.